230 related articles for article (PubMed ID: 1778314)
21. The reaction of bacterial toxins with formaldehyde and its use for antigen stabilization.
Petre J; Pizza M; Nencioni L; Podda A; De Magistris MT; Rappuoli R
Dev Biol Stand; 1996; 87():125-34. PubMed ID: 8854009
[TBL] [Abstract][Full Text] [Related]
22. Preparation and characterization of Pertussis toxin subunits.
Sheu GC; Wo YY; Lu CH
Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi; 1997 Aug; 30(3):182-93. PubMed ID: 10592823
[TBL] [Abstract][Full Text] [Related]
23. Characterization of mutant strains producing pertussis toxin cross reacting materials.
Sato Y; Sato H; Chazono M; Ginnaga A; Tamura C
Dev Biol Stand; 1991; 73():93-107. PubMed ID: 1778339
[TBL] [Abstract][Full Text] [Related]
24. Potency assay and characterization of lymphocytosis promoting factor in whole cell and acellular pertussis vaccines.
Tiru M; Falk A; Brym-Grynblat B; Pettersson IM
Dev Biol Stand; 1991; 73():157-65. PubMed ID: 1778309
[TBL] [Abstract][Full Text] [Related]
25. Anti-pertussis toxin IgG and anti-filamentous hemagglutinin IgG production in children immunized with pertussis acellular vaccine and comparison of these titers with the sera of pertussis convalescent children.
Sato Y; Sato H
Dev Biol Stand; 1985; 61():367-72. PubMed ID: 3835079
[TBL] [Abstract][Full Text] [Related]
26. Aerosol infection test for evaluation of pertussis vaccine.
Syukuda Y; Watanabe H; Suehara A; Fujii S; Kuno-Sakai H; Kimura M
Tokai J Exp Clin Med; 1988; 13 Suppl():71-7. PubMed ID: 2908529
[TBL] [Abstract][Full Text] [Related]
27. [An observation on immunization reaction and serological effect of adsorbed purified pertussis vaccine].
Tian X
Zhonghua Liu Xing Bing Xue Za Zhi; 1993 Jun; 14(3):155-9. PubMed ID: 8221838
[TBL] [Abstract][Full Text] [Related]
28. Quantification of pertussis toxin, filamentous haemagglutinin, 69 kDa outer membrane protein, agglutinogens 2 and 3 and lipopolysaccharide in the Danish whole-cell pertussis vaccine.
Ibsen PH; Petersen JW; Heron I
Vaccine; 1993; 11(3):318-22. PubMed ID: 8447160
[TBL] [Abstract][Full Text] [Related]
29. Acellular Bordetella pertussis vaccine enhances mucosal interleukin-10 production, induces apoptosis of activated Th1 cells and attenuates colitis in Galphai2-deficient mice.
Ohman L; Willén R; Hultgren OH; Hultgren Hörnquist E
Clin Exp Immunol; 2005 Jul; 141(1):37-46. PubMed ID: 15958068
[TBL] [Abstract][Full Text] [Related]
30. Studies on the optimal conditions for inactivation of Bordetella pertussis organisms with glutaraldehyde for preparation of a safe and potent pertussis vaccine.
Gupta RK; Saxena SN; Sharma SB; Ahuja S
Vaccine; 1988 Dec; 6(6):491-6. PubMed ID: 2907704
[TBL] [Abstract][Full Text] [Related]
31. [A polyvalent complex of Bordetella pertussis antigens as the basis for an acellular pertussis vaccine].
Zakharova NS; Shmeleva EI; Remova TN; Bazhanova IG; Ozeretskovskaia MN; Mertsalova NU; Britsina MV; Ermolova EV; Zaĭtsev EM
Zh Mikrobiol Epidemiol Immunobiol; 1997; (3):70-2. PubMed ID: 9304336
[TBL] [Abstract][Full Text] [Related]
32. [Humoral response to the injection of acellular Pertussis vaccine].
Zakharova NS; Remova TN; Britsina MV; Shmeleva EI; Mertsalova NU; Zaĭtsev EM; Ozeretskovskaia MN; Bazhanova IG; Ermolova EV
Zh Mikrobiol Epidemiol Immunobiol; 2001; (6):40-4. PubMed ID: 11881494
[TBL] [Abstract][Full Text] [Related]
33. A novel process for preparing an acellular pertussis vaccine composed of non-pyrogenic toxoids of pertussis toxin and filamentous hemagglutinin.
Tan LU; Fahim RE; Jackson G; Phillips K; Wah P; Alkema D; Zobrist G; Herbert A; Boux L; Chong P
Mol Immunol; 1991 Mar; 28(3):251-5. PubMed ID: 2017196
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of chemically cross-linked antigens for acellular pertussis vaccine.
Watanabe M; Nagai M; Funaishi K; Endoh M
Vaccine; 2000 Dec; 19(9-10):1199-203. PubMed ID: 11137257
[TBL] [Abstract][Full Text] [Related]
35. Characteristics and potency of an acellular pertussis vaccine composed of pertussis toxin, filamentous hemagglutinin, and pertactin.
Sheu GC; Wo YY; Yao SM; Chou FY; Hsu TC; Ju CL; Cheng Y; Chang SN; Lu CH
J Microbiol Immunol Infect; 2001 Dec; 34(4):243-51. PubMed ID: 11825003
[TBL] [Abstract][Full Text] [Related]
36. A Bordetella pertussis acellular vaccine candidate: antigenic characterization and antibody induction.
Dias WO; Horton DS; Takahashi CM; Raw I
Braz J Med Biol Res; 1994 Nov; 27(11):2607-11. PubMed ID: 7549983
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of pertussis vaccines consisted of antigens detoxified with tea-leaf catechins.
Watanabe M; Funaishi K; Takeo T; Endoh M
Vaccine; 2000 Dec; 19(9-10):1204-10. PubMed ID: 11137258
[TBL] [Abstract][Full Text] [Related]
38. [The development of a new generation of pertussis vaccine].
Chuprinina RP; Bychenko BD; Smirnov VD; Maksiutov RV; Eglit IuKh
Zh Mikrobiol Epidemiol Immunobiol; 1990 Oct; (10):89-94. PubMed ID: 2075771
[TBL] [Abstract][Full Text] [Related]
39. The effects of purified pertussis components and lipopolysaccharide on the results of the mouse weight gain test.
Gupta RK; Saxena SN; Sharma SB; Ahuja S
J Biol Stand; 1988 Oct; 16(4):321-31. PubMed ID: 3198661
[TBL] [Abstract][Full Text] [Related]
40. Comparative biological activities of whole cell pertussis vaccine and a new acellular preparation.
García-Sánz JA; Ruiz-Puente J; Jiménez-Paredes J; González-Pacheco M; Villalva-Posada H
Vaccine; 1985 Mar; 3(1):23-6. PubMed ID: 4039870
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
